Introduction:
Low-grade gliomas can appear in any region of the neuroaxis. When
located in particular areas of the brain, seizures can be a common
manifestation at diagnosis. Characteristically, temporal-mesial and
insular lobe areas tend to harbor such lesions (1). Not infrequently,
tumor-associated epilepsy may be hard to control and even refractory to
multiple antiepileptic drugs (AED). In the context of long-term epilepsy
associated tumors (LEATS), extensive neurosurgical interventions are
usually necessary to improve seizures control (2). Quality of life of
children and adolescents under multiple AED and/or with post-surgical
neurologic sequelae must be taken into consideration when proposing a
treatment plan for these challenging patients. Frequently, these tumors
tend to present an aberrant activation of MAPK signaling either through
a BRAF tandem duplication or V600E mutation. The
development and introduction of oral targeted therapies includingBRAF inhibitors are changing the treatment paradigm for these
patients. However, its clinical efficacy in tumor-associated epilepsy
has not been reported.